The Prospective MOSCATO 01 Trial Demonstrates that Molecular "Portraits" Improve Outcome of Patients with Metastatic Cancer - Seite 2

Pr Gilles Vassal, Head of Clinical Research at Gustave Roussy, stated "MOSCATO is one among 12 trials deployed within the precision medecine initiative at Gustave Roussy. However it is the first trial to demonstrate in a prospective manner that precision medecine improves survival. This trial has requested a strong and large commitment from the whole institution, leveraging on multiple expertises: clinical teams, interventional radiologists, bio-pathologists, bio-informaticians, bio-statisticians, as well as clinical research and sponsoring personnel".

"Among the 411 patients with an actionable target (49% of all enrolled patients with an available biopsy), 199 patients were treated with an ad hoc targeted therapy (19% of all enrolled patients with an available biopsy)." stated Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy.

To evaluate the clinical benefit of the targeted therapy, the patient was used as its own control. The progression-free survival (PFS) from the most recent therapy on which the patient had just experienced progression before enrolment in MOSCATO was established for each patient. This PFS was compared to the PFS observed under the targeted therapy selected within the MOSCATO trial. Indeed, it is well established in oncology that as patients progress across multiple lines of therapies, PFS durations tend to decrease at each consecutive new line. The vast majority of the targeted therapies selected within the MOSCATO trial, where those available within open phase I trials running at Gustave Roussy (over 60 phase 1 trials are currently enrolling patients within the Drug Development Department at Gustave Roussy).

33% of patients treated within the MOSCATO trial had an improved outcome (at least a 30% increase of their PFS with the targeted therapy as compared to their baseline reference PFS). Moreover, 62% of the patients had disease control (ie objective response or stable disease). 

"While SAFIR 01 has proven the feasibility of performing complex molecular characterisation of tumours in daily clinical practice, the MOSCATO trial demonstrates that this approach is effective to improve cancer patients'outcome" highlighted Pr Jean-Charles Soria.

Source : The MAP meeting, 23rd of september 2016, London- http://www.map-onco.net/